Literature DB >> 2787408

Lack of interference by the unnatural isomer of 5-formyltetrahydrofolate with the effects of the natural isomer in leucovorin preparations.

R Bertrand1, J Jolivet.   

Abstract

Leucovorin, a mixture of the natural (6S) and unnatural (6R) diastereomers of 5-formyltetrahydrofolate, is administered clinically to enhance the antitumor activity of 5-fluorouracil. Because the 6R isomer persists at high concentrations in plasma for prolonged periods after iv leucovorin administration (J Clin Oncol 4:685-696, 1986), we have examined it to ascertain whether the 6R isomer could interfere with the cellular effects of the 6S isomer. The 6R compound had a poorer uptake into human CCRF-CEM lymphoblastic cells than the 6S compound, but the 6R compound could competitively inhibit the uptake of the natural isomer as determined in defined buffers. However, the 6R compound failed to interfere with cell growth support and enhancement of 5-fluorouracil cytotoxicity by the 6S isomer in CCRF-CEM cells in tissue culture experiments at concentrations up to 1 mM. Thus, the unnatural isomer of 5-formyltetrahydrofolate present in leucovorin preparations seems unlikely to have clinically relevant consequences.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787408     DOI: 10.1093/jnci/81.15.1175

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

1.  Inhibition of thymidylate synthase by the diastereoisomers of leucovorin.

Authors:  P P Lee; R L Schilsky
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Pharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer.

Authors:  S Stremetzne; M Streit; E D Kreuser; W Schunack; U Jaehde
Journal:  Pharm World Sci       Date:  1999-08

3.  Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer.

Authors:  R M Mader; G G Steger; B Rizovski; A E Sieder; G Locker; M F Gnant; R Jakesz; H Rainer
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

4.  Regulation of T cell proliferation with drug-responsive microRNA switches.

Authors:  Remus S Wong; Yvonne Y Chen; Christina D Smolke
Journal:  Nucleic Acids Res       Date:  2018-02-16       Impact factor: 16.971

5.  A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma.

Authors:  N J Meropol; N J Petrelli; Y M Rustum; M Rodriguez-Bigas; L E Blumenson; C Frank; E Berghorn; P J Creaven
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

6.  Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies.

Authors:  F H Valone; D R Gandara; J A Luce; S Wall; E A Perez; N Braham; M George; L Letvak
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines.

Authors:  M C Etienne; S Bernard; J L Fischel; P Formento; J Gioanni; J Santini; F Demard; M Schneider; G Milano
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

8.  Comparative effect of 6S, 6R and 6RS leucovorin on methotrexate rescue and on modulation of 5-fluorouracil.

Authors:  J Zittoun; J Marquet; J J Pilorget; C Tonetti; E De Gialluly
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

9.  Critical factors for the reversal of methotrexate cytotoxicity by folinic acid.

Authors:  S Bernard; M C Etienne; J L Fischel; P Formento; G Milano
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.